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risk of stroke, the most likely explanation for which is 
embolisation of thrombus to the systemic circulation 
during removal of the thrombectomy catheter.
Is selective use of thrombectomy in selected patients 
reasonable? None of the subgroup analyses in TOTAL, 
including patient age, presence of diabetes, coronary 
ﬂ ow grade, smoking status, location of infarction, 
or type of anticoagulation used during the invasive 
procedure provide support for this idea. Thrombectomy 
might help improved lesion overview, direct stenting, 
stent sizing, and apposition, and could serve as a bailout 
treatment in no-reﬂ ow scenarios, but we must weigh 
up the potential beneﬁ ts in individual cases against 
the overall absence of positive eﬀ ects and the small 
associated risk of stroke.
In the European Union and elsewhere, introduction of 
new medical devices, such as thrombectomy catheters, 
is not as tightly regulated as is the introduction of 
new pharmaceutical therapies. Although this situation 
might oﬀ er advantages to patients in terms of timely 
access to important device innovations, it leads to poor 
clinical assessment and an increased risk of unexpected 
complications and absence of beneﬁ t. The problem 
is not conﬁ ned to invasive cardiology—almost 8% of 
primary hip replacement prostheses implanted in the 
UK do not have evidence for clinical eﬀ ectiveness and 
longevity.12 The 1-year results from TASTE and TOTAL 
should serve as a caveat against the introduction of 
new medical techniques and devices into routine 
clinical use until clinical endpoint data from adequately 
powered trials or data from high-quality health 
registries are available.
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Genetics and phenotypes in inﬂ ammatory bowel disease
Inﬂ ammatory bowel diseases, encompassing Crohn’s 
disease and ulcerative colitis, have long been recognised 
as very heterogeneous dis eases at the clinical level. 
Farmer and colleagues1 were among the ﬁ rst to report 
that location of disease was a major driver for disease 
presentation, complications, and rates of surgery. More 
recently, the Montreal and Paris classiﬁ cations (ie, 
modiﬁ ed Montreal classiﬁ cation for use in paediatric 
inﬂ ammatory bowel disease) have tried to standardise 
clinical phenotypes further, acknowledging that age at 
diagnosis, and location and extent of disease in Crohn’s 
disease and ulcerative colitis, and disease behaviour in 
Crohn’s disease, are the main factors aﬀ ecting disease 
course and prognosis.2,3 For example, younger age at 
diagnosis is generally associated with more extensive 
and aggressive disease in both Crohn’s disease and 
ulcerative colitis; ileal (L1) and ileocolonic (L3) Crohn’s 
disease are more frequently associated with stenosing 
and ﬁ stulising complications and need for surgery than 
is colonic Crohn’s disease (L2); and in ulcerative colitis, 
extensive disease (E3) usually has higher therapeutic 
requirements, risk of colorectal cancer, and rates of 
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hospital admission and surgery than does non-extensive 
disease (E1 and E2).2 
The phenotypic concordance reported in familial cases 
of inﬂ ammatory bowel disease and in monozygotic twins 
with inﬂ ammatory bowel disease has long served as an 
argument that shared environmental and genetic factors 
shape disease phenotype.4,5 Beginning with the early 
linkage studies, and continuing through identiﬁ cation of 
the NOD2 gene until the most recent era of genome-wide 
association studies, progress has been enormous, 
culminating in the identiﬁ cation of 163 independent 
loci associated with inﬂ ammatory bowel disease.6 We 
have learned that Crohn’s disease and ulcerative colitis 
share several disease susceptibility loci, many of which 
are implicated in other immune-mediated diseases.6 
Furthermore, the discoveries of genes related to 
T-helper-17 cell diﬀ erentiation and function, and genes 
inﬂ uencing innate immunity and microbial immune 
response, have brought major insights into disease 
pathogenesis, pointing to altered bacterial handling as a 
key factor in disease pathogenesis.7 
Clearly, the next logical step would be to dissect 
genotype–phenotype relations, in the hope of identifying 
inﬂ ammatory bowel disease subtypes that could be 
translated into the clinic. In The Lancet, Isabelle Cleynen 
and colleagues8 report the largest genotype–phenotype 
study ever undertaken in inﬂ ammatory bowel disease. 
The investigators are to be congratulated for the 
enormous international collaborative eﬀ ort, with detailed 
phenotypic data gathered for many patients with 
inﬂ ammatory bowel disease, and for their meticulous 
and well designed statistical methodology. Overall, 
29 838 patients with inﬂ ammatory bowel disease 
were genotyped with the Immunochip array (designed 
to capture almost 200 diﬀ erent loci associated with 
common autoimmune diseases), and variants in the MHC 
were imputed. That important phenotypic conclusions 
would be drawn from such a well powered study might be 
expected; unfortunately, this was not the case.
The major ﬁ ndings were, ﬁ rst, that the previously 
proposed relation between NOD2 and stenosing disease 
is not a true one; rather, it is driven by NOD2 association 
with young age at diagnosis and ileal location; and 
second, that colonic disease location (L2) for Crohn’s 
disease was better predicted by the HLA susceptibility 
alleles of ulcerative colitis than by the susceptibility alleles 
of Crohn’s disease. To investigate this ﬁ nding further, 
the researchers resorted to predictive models of disease 
location and showed that colonic Crohn’s disease is 
genetically intermediate between ileal Crohn’s disease 
and ulcerative colitis. Cleynen and colleagues8 conclude 
that colonic Crohn’s disease is genetically distinct from 
ileal Crohn’s disease, and propose a new nomenclature for 
inﬂ ammatory bowel disease (however, L3 disease—the 
most common disease location—is inexplicably left out).
Only three main loci (NOD2, MHC, and 3p21/MST1) 
achieved genome-wide signiﬁ cance for association 
with clinical phenotypes in Cleynen and colleagues 
study,8 but when combined in a predictive model with 
Figure: Phenotypes in inﬂ ammatory bowel disease: the contribution of genetics
IBD=inﬂ ammatory bowel disease. UC=ulcerative colitis. CD=Crohn’s disease. EIM=extra-intestinal manifestations. 
Montreal classiﬁ cation for disease location: L1, ileal disease; L2, colonic disease; L3, ileocolonic disease; L4, upper 
gastrointestinal disease. Disease extent: E1, proctitis; E2, left-sided colitis; E3, extensive colitis. Disease behaviour: 
B1, inﬂ ammatory; B2, stricturing; B3, penetrating disease.
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Coronary artery disease is the largest contributor to 
cardiovascular diseases and the number one cause of 
death in western countries. Percutaneous coronary 
intervention (PCI) has become the most commonly 
done interventional procedure in medicine, and 
coronary artery bypass grafting (CABG) has become 
one of the most commonly done forms of major 
surgery.1,2 The number of CABG operations done each 
year has remained constant, whereas the number of 
PCI procedures has increased and now accounts for an 
increasing proportion of revascularisation procedures.3 
Patients with complex lesions often still require CABG 
because of the signiﬁ cantly higher adverse event rates 
with PCI that are largely attributable to increases in rates 
of repeat revascularisation.4 Incomplete revascularisation 
is one of the reasons for adverse outcomes after PCI, and 
Coronary artery disease: a dam in the river for ranolazine
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clinical–demographic factors, these loci were unable to 
explain disease variance. Next to NOD2, age at diagnosis 
and smoking were the main drivers for disease location 
in adult Crohn’s disease, whereas, for ulcerative colitis, 
age at diagnosis was the most important determinant of 
disease extent, albeit of modest eﬀ ect.
The feeble tone of our criticism merely reﬂ ects our 
disappointment that, in essence, Cleynen and colleagues’ 
strongly powered study,8 which focused mainly on 
genetic factors, provides only limited new phenotypic 
insights. No genetic loci associated with perianal disease, 
upper gastrointestinal disease, or extra-intestinal 
manifest ations were identiﬁ ed. No genetic predictors 
of disease progression in Crohn’s disease, or of disease 
extent or proximal extension in ulcerative colitis, could 
be detected (ﬁ gure).
So how should we interpret the results? As pointed out 
by Cleynen and colleagues, the analysis was restricted to 
the known variants determining disease risk, and therefore 
it is possible that important loci inﬂ uencing disease course 
remain to be identiﬁ ed. For example, rare variants with 
larger eﬀ ects could have a profound eﬀ ect in disease 
subphenotypes. Novel approaches such as whole-genome 
and exome sequencing will perhaps bring additional 
insight. Fundamentally, it is clear that gene–environment 
connections need to be more systematically interrogated. 
Epigenetic factors, mediating the interactions between 
genetics and complex environmental exposures such as 
the microbiome, could potentially provide new clues to 
disease pathogenesis in the years to come.9,10 Importantly, 
many of the classic clinical and epidemiological ﬁ ndings—
such as the relation with smoking, the macroscopic 
distribution of disease, and the mesenteric fat 
hypertrophy in Crohn’s disease—remain to be explained.11 
Cleynen and colleagues’ study highlights the urgent need 
for innovative thinking and the development of a new 
research roadmap that systematically integrates genetic 
with non-genetic factors.
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